

06-19-00

A

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. SD9-141-2
First Inventor or Application Identifier Sanjay Nigam
Title EX-VIVO PROPAGATION OF KIDNEY
Express Mail Label No. EK689623164US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages 32]
(preferred arrangement set forth below)
- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 11]
4. Oath or Declaration [Total Pages 2]
a. ☒ Newly executed (original or copy)
b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
a. ☐ Computer Readable Copy
b. ☐ Paper Copy (identical to computer copy)
c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☒ Assignment Papers (cover sheet & document(s))
8. ☐ 37 C.F.R. § 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
11. ☐ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
13. ☒ * Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)
14. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
15. ☐ Other: _____

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____

Prior application information: Examiner _____

Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence address below

Name FUESS & DAVIDENAS
Address 17258 Amarillo Rd.
City Ramona State CA Zip Code 92065
Country Telephone 760 788-7401 Fax 760 788-5846

Name (Print/Type) William C. Fuess Registration No. (Attorney/Agent) 30,054
Signature William C. Fuess Date 6/16/2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sanjay Nigam
Attorney's Docket No.: SD9-141-2
Title: EX-VIVO PROPAGATION OF KIDNEY
UCSD Case No.: SD99-141-2

VERIFIED STATEMENT UNDER 37 CFR §1.9(f) AND §1.27(d)
CLAIMING STATUS AS A SMALL ENTITY - NONPROFIT ORGANIZATION

I, Dr. Alan Paau, Director of the Technology Transfer Office of the University of California, San Diego, hereby declare that:

1. I am empowered to act on behalf of THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a corporation duly organized under and pursuant to the laws of CALIFORNIA having its principal place of business at 1111 Franklin Street, 5th Floor, Oakland California 94607-5200, in the matter of this VERIFIED STATEMENT.

2. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA is a University of higher education of the State of California and a nonprofit organization.


3. The rights under contract or law in the invention contained within the above-identified patent application are obligated to be assigned to and remain with THE REGENTS OF THE UNIVERSITY OF CALIFORNIA. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA has not assigned, granted, conveyed or licensed, and is under no obligation under contract or law to assign, grant, convey or license any rights in the invention nor in the application to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR §1.9(d) or a non-profit organization under 37 CFR §1.9(e).

4. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA qualifies as a nonprofit organization as defined in 37 CFR §1.9(e) for paying reduced fees under section 41 subsections (a) and (b) of Title 35, United States Code, with regard to said application.

5. I acknowledge the duty under 37 CFR §1.28(b) to file, in this application or any patent issuing thereon, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of any issuance fee or any maintenance fee due after that date on which status as a small entity is no longer appropriate.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent(s) issuing thereon.

6/14/2000
Date


Signature of Alan Paau, MBA, Ph.D.
Director, Technology Transfer Office
University of California San Diego
9500 Gilman Drive, MC 0910
La Jolla, CA 92093-0910
Representative of THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

EX-VIVO PROPAGATION OF KIDNEY

BACKGROUND OF THE INVENTION

Field of the Invention

5 The present invention generally concerns a new method of engineering a kidney *in vitro*.

 The present invention particularly concerns a new method and procedure for propagating cloned kidney members from embryonic ureteric bud tips grown *in vitro* under specific culture conditions.

10 Description of Related Art

 Branching tubulogenesis is an essential mechanism by which epithelial tissues such as kidney, salivary gland and prostate develop (Proc. Natl. Acad. Sci. USA, 96, 7330-7335, 1999 incorporated herein by reference). Largely based on the classical studies of Grobstein and coworkers, direct interactions between mesenchymal and
15 epithelial components of embryonic tissue have been thought to be crucial for branching morphogenesis in most epithelial tissues (1,2,3). During kidney development, for example, direct cell-cell interactions between the metanephric mesenchyme and the epithelial component, the ureteric bud (UB), are believed to be essential for branching morphogenesis of the latter (4,5,6). This view is based on the
20 fact that it had not been possible, in many previous studies, to observe proliferation and branching of the UB in the absence of direct contact with the metanephric mesenchyme or another inducing tissue, suggesting that the developmental program

necessary for branching depended upon direct contact between surface proteins of the UB with surface proteins of the metanephric mesenchyme. Furthermore, no known soluble factor or set of factors had been able to induce UB branching morphogenesis *in vitro* (7).

5 This view has gained additional support from knockout experiments in which absent expression of a variety of individual soluble growth factors held to be important in kidney development, based upon previous organ culture experiments, fail to show defective branching morphogenesis of the UB (8,9). Nevertheless, recent studies have also shown that glial cell line derived neurotrophic factor
10 (GDNF) is necessary for early UB outgrowth (10,11,12,13,14,15), but on its own, it fails to promote proliferation and branching morphogenesis of isolated UB *in vitro*. These results left open the possibility that some unknown soluble factor, or combination of factors, derived from the metanephric mesenchyme, might be sufficient to induce epithelial branching morphogenesis.

15 *A wide array of renal and urological abnormalities are likely due to defective tubulogenesis and branching morphogenesis of the developing collecting system*

It is now clear that a variety of defects in the kidney and urinary collecting system are the result of abnormal development of these structures in the fetus. The spectrum of disease is huge, as is their potential morbidity. The molecular basis for these diseases
20 is poorly understood; however, it appears, in many instances, that the problem lies in defective morphogenesis of the ureteric bud. The urinary collecting system (from the trigone of the bladder including ureteral orifices, ureters, renal pelvis, and collecting tubules) arises from the UB. Thus, developmental abnormalities of the UB and its derivatives would be expected to give rise to a variety of "urological" as well as

"nephrological" clinical syndromes. Developmental anomalies extrinsic to the kidney, but in principle attributable to defects in UB morphogenesis, include vesicoureteral reflux (VUR), ureteropelvic junction obstruction (UPJO), ectopic and duplicated ureters. Since normal kidney development depends critically upon mutual
5 inductive interactions between the UB and the metanephric mesenchyme (MM), inefficient or defective branching morphogenesis of the UB would be expected to result in various aplastic, hypoplastic, and perhaps dysplastic diseases. Extrinsic collecting system abnormalities would then be expected to, coexist with various hypoplastic diseases of the kidney. In fact, up to 1/3 of end stage renal disease in
10 children is due to developmental problems, the majority of which may be categorized as ureteral with or without dysplasia or hypoplasia of one or both kidneys. In addition, perhaps 5-10% of all adults has some occult developmental anomaly.

Recent advances in the molecular biology of kidney development demonstrate that specific molecular defects can explain a variety of clinical syndromes. VUR,
15 UPJO, and various dysplastic, and hypoplastic kidney disorders have been known to co-exist and to be expressed in various human lineages with a variable penetrance, the so-called CAKUT syndrome. In addition, several targeted gene-deletion experiments have resulted in phenotypes that may be best characterized as resulting from defective UB morphogenesis (directly or indirectly). These range from the
20 renal aplasia associated with complete UB failure associated with deletions of WT-1 and the RTK c-ret molecules to more subtle effects resulting in hypoplasia or oligonephronia such as seen with certain integrin knockouts (34, 46). Defective collecting system development may play a role in the most common congenital cystic disease, ADPKD. The inventors have shown that expression of PKD-1 correlates
25 spatiotemporally with branching morphogenesis of the UB (21). Findings such as

this have led to the hypothesis that ADPKD and other cystic diseases of the kidney result from defects in the developmental program necessary for proper tubulogenesis.

Aside from "congenital" disease per se, defective collecting system development may underlie predisposition to disease much later in life. It has been argued that low
5 nephron number is crucial to the development of hypertension and chronic renal failure in adults. This may well be the result of defective branching morphogenesis during development of the urinary collecting system, because the degree of ureteric bud branching during collecting system development determines the number of nephrons in the adult kidney. Hence, aggregate nephron number is a function of
10 factors regulating ureteric bud branching during urinary tract development. If one assumes a 1 % decrement in efficiency of branching morphogenesis (99% efficient at all steps), this results in less than half the normal number of nephrons after the roughly 20 generations of branching which occur during human nephrogenesis.

In summary, a broad spectrum of disorders ranging from urological abnormalities,
15 hypoplasia, dysplasia, and cystic diseases, and possibly even certain forms of "essential" hypertension, may be viewed as developmental diseases of ureteric bud and its derivatives. Recent work indicates that a molecular basis exists for these disorders and that much human morbidity and mortality may be attributable to varying degrees of failure in the process of ureteric bud branching morphogenesis.

20 *The cellular and molecular basis of development of the urinary collecting system, particularly tubulogenesis and branching morphogenesis, are not well understood*

In the mouse, inductive interactions between the MM and the UB that are necessary for formation of the metanephric kidney take place around embryonic day 11; in the rat, this occurs around day 13. Through *in vitro* organ and cell culture

studies, as well as knockouts, both soluble factor influence and cell-cell contact have been implicated, although the exact nature of the inducing signals is a topic of intense investigation and debate. Subsequent to these interactions, the metanephric mesenchyme undergoes a “mesenchymal to epithelial transition,” during which it
5 acquires epithelial markers such as cytokeratins. As development progresses, the recently epithelialized mesenchyme forms early nephronal structures, which ultimately develop into the proximal through distal tubule. All this appears to be guided by interactions with the ureteric bud as it, through a process of branching morphogenesis, develops into the collecting system. Thus, while the mesenchyme is
10 differentiating, the ureteric bud is invading it and undergoing iterations of symmetric and asymmetric dichotomous branching. About 20 generations of such branching events result in the roughly 1 million collecting ducts that form the renal portion of the urinary collecting system.

This general process is not unique to the kidney. Branching tubulogenesis
15 (ductogenesis) is an essential mechanism by which most, if not all, epithelial tissues form in the embryo. Largely due to the classical studies using organ culture, direct interactions between mesenchymal and epithelial components of embryonic tissue have been thought to be crucial for branching morphogenesis in kidney and urinary tract. This view is based on the fact that it had not been possible, in many previous
20 studies, to observe proliferation and branching of the UB in the absence of direct contact with the metanephric mesenchyme or another inducing tissue, suggesting that the developmental program necessary for branching depended upon direct contact between surface proteins of the UB with surface proteins of the metanephric mesenchyme. Furthermore, no known soluble factor or set of factors had been able
25 to induce UB branching morphogenesis *in vitro*. This view has gained additional

support from knockout experiments in which absent expression of a variety of individual soluble growth factors held to be important in kidney development (based upon previous organ culture experiments) fail to show defective branching morphogenesis of the UB. Nevertheless, recent studies have demonstrated that glial cell line derived neurotrophic factor (GDNF) is necessary for early UB outgrowth, but as the inventors have shown, on its own, it fails to promote proliferation and branching morphogenesis of isolated UB *in vitro* (Fig. 6). [Proc. Natl. Acad. Sci., 96, 7330-7335, 1999 incorporated herein by reference].

The primary focus of this invention is to present a novel method and procedure for propagation of cloned kidney members from embryonic ureteric bud which also has applicability to other epithelial-derived tissues. This method differs in concept and substance from US Patent No. 6,060,270 (May 09, 2000) issued to Humes. In contrast to the Humes patent, this method employs the intrinsic ability of the embryonic epithelial tissue to branch in order to generate an indefinite number of organs from a single embryonic ureteric bud. Thus, in principle, after six generations of branching, a single ureteric bud can give rise to 256 (2^8) kidneys or even more, depending upon the number of generations the ureteric bud is allowed to branch in culture.

SUMMARY OF THE INVENTION

The primary object of this invention is to provide functioning replacement organs or functional fragments thereof that are suitable for transplanting into recipients suffering from a variety of life-threatening diseases or developmental anomalies.

Another object in accordance with the present invention is to generate

functional mammalian epithelium-derived organs, or active fragments thereof from embryonic explants, tissues or cells utilizing *in vitro* culture techniques.

Another object of this invention is to define soluble inducing factors effective in transforming embryonic epithelial cells or tissues into regenerating functional
5 organs, glands and the like.

A further, most preferred object is to provide a bank of embryonic organs and tissues capable of replacing diseased, or otherwise incapacitated vital organs and tissues, minimizing the need for matching donors and/or immunosuppressive drugs.

In accordance with these objects, this invention contemplates a method for
10 constructing a functional mammalian tubulogenic organ or fragment thereof *in vitro*. The method involves culturing and propagating embryonic explants, tissues or cells by isolating said explants, tissues or cells and growing them in culture with specific soluble and insoluble inducers for sufficient periods of time to allow the cultured specimens to form multiple branches. The tips of these branches are then dissected
15 out and recultured in the presence of serum, growth factor mix, mixture of conditioned and nutrient-rich medium for several generations to form 3-dimensional tubulogenic structures with multiple growing tips. This process can proceed *ad infinitum* under proper culture conditions having effective inducer substances.

The contemplated method further involves culturing and propagating
20 embryonic mesenchymal tissues capable of inducing limited differentiation and directional growth to form functional organs or tissues. The mesenchymal or other inducing tissue fragments are dissected out at the time of induction, and cultured in the presence of serum, growth factor mix, and a mixture of appropriate conditioned medium and nutrient-rich medium. After several passages in primary culture,

growing inductive tissue may be partitioned into multiple fragments. Each fragment can then grown separately in culture. Vasculogenesis within each fragment is induced by substrate deprivation and/or the addition of specific soluble factors.

Finally, a grown, vascularized tissue fragment is combined in coculture with a
5 cultured tubulogenic fragment described hereinabove, in a matrix in which *in vitro* angiogenesis has begun. The two tissue fragments are grown in nutrient-rich medium conditions to enable continued vasculogenesis. Alternatively, the “cloned” kidney can be implanted for in vivo vascularization.

A more specific and preferred embodiment of this invention is a method for
10 generating a functional mammalian kidney *in vitro* by culturing and propagating ureteric bud tissue. This method comprises isolating embryonic kidney rudiments by dissection, isolating ureteric bud tissue fragments from mesenchyme by incubating the kidney rudiments with a proteolytic enzyme in the presence of DNAase and/or by mechanical separation. The isolated ureteric bud fragments are suspended in a gel
15 matrix and the gel/fragment composition is placed on porous polycarbonate membrane inserts in wells of tissue culture plates. Growth factors are added to the culture wells, and the gel composition comprising the bud fragments is maintained at the interface of air and medium until the fragments form multiple tubular branches inside the gel matrix. Individual distal branch tips formed during culture are
20 dissected out and recultured in the presence of serum, growth factor mix, mixture of mesenchymal and ureteric bud cell conditioned medium and nutrient-rich medium for several generations.

The mechanical separation of tissue fragments can be accomplished by manual dissection or laser separation and capture. The growth factor mix includes

glial cell line-derived neurotrophic factor or functional equivalent thereof. The added conditioned medium contains a heretofore-unidentified growth promoting constituent and/or inducer of differentiation. The extracellular matrix gel comprises a mixture of type I collagen and Matrigel or a comparable support matrix.

5 An equally preferred embodiment in accordance with this invention is method for simultaneous *in vitro* culturing and propagation of metanephric mesenchyme. This method comprises dissecting out fetal kidney mesenchyme tissue at the time of induction, culturing fragments of the mesenchymal tissue in the presence of serum, growth factor mix, mixture of mesenchymal and bud cell conditioned medium and
10 nutrient-rich medium, and partitioning the cultured mesenchyme into multiple pieces. Each piece is grown separately in culture for several generations and grown mesenchyme is then subjected to substrate deprivation and/or additional growth factors in order to induce vasculogenesis.

 A most preferred embodiment in accordance with this invention is a method
15 for *in vitro* engineering and constructing a functioning mammalian kidney by culturing and propagating an isolated ureteric bud, permitting the cultured bud to form multiple branches, dissecting out the individual branch tips, and reculturing in the presence of serum, growth factor mix, mixture of mesenchymal and bud cell conditioned medium and nutrient-rich medium for several generations. The method
20 also comprises simultaneously culturing and propagating isolated embryonic or fetal metanephric mesenchyme by dissecting out fetal mesenchyme at the time of induction, culturing mesenchymal tissue in the presence of serum, growth factor mix, mixture of mesenchymal and bud cell conditioned medium and nutrient-rich medium, potentially partitioning the mesenchyme into multiple pieces with the option of
25 growing each piece separately, and inducing vasculogenesis by subjecting grown

mesenchyme to substrate deprivation. The most preferred method then provides for recombining each vascularized mesenchyme piece with each cultured bud in a matrix in which *in vitro* angiogenesis has begun, and growing in richest medium conditions to ensure continued vasculogenesis.

5 Thus, in the most preferred embodiment, is a functional mammalian kidney constructed from isolated embryonic or fetal kidney tissue or cells cultured in rich medium that has present a mixture of growth factors and inducer substances, and comprises recombination of an isolated ureteric bud propagated in culture to produce a functioning nephron, and metanephric mesenchyme propagated from cultured
10 embryonic mesenchymal tissue fragments or cells. Said mesenchyme has the capability of inducing differentiation and providing directional guidance to the branching tubulogenic bud.

 Still further embodiments and advantages of the invention will become apparent to those skilled in the art upon reading the entire disclosure contained
15 herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: A schematic representation of the methodology and salient points of this invention. A schematic diagram showing a novel culture method for inducing *in vitro* branching morphogenesis of an isolated ureteric bud (UB), simultaneous culture
20 of mesenchymal tissue and recombination and coculturing of the two cultured tissue fragments. The mesenchymal tissue added to the bud culture induces the bud to directionally extend branching tubules and further differentiate and incorporate to form a functioning nephron, capable of absorbing, filtering, collecting and secreting body fluids. Schematically depicted is a ureteric bud fragment in culture 2, being

induced by a stimulant(s) to produce a pluripotent fragment **3**, that is capable of branching morphogenesis to form a branched three-dimensional structure **4**. It can be seen that an excised growing tip **2** can be further cultured in the presence of an inducer(s) **1** to again form an activated fragment **3**, that will continue its tubulogenic morphogenesis. Simultaneously, an isolated fragment of mesenchymal tissue **5** is grown in culture to produce multiple pieces of mesenchymal tissue. One such piece **6** is grown and is then placed in coculture with an actively branching bud fragment **7**. The bud fragment, under influence of the mesenchymal induction continues to branch in a now directed fashion and to further differentiate to form maturing effluent collecting tubules, enlarging as the branching progresses to accommodate increased effluent and incorporating into new nephrons. Eventually an embryonic kidney, or a functionally equivalent fragment thereof, is formed **8**.

Figure 2: A novel culture system for *in vitro* branching morphogenesis of the ureteric bud (UB) (Proc. Natl. Acad. Sci., 96, 7330-7335, 1999 incorporated herein by reference—please refer to this paper for color reproductions). UBs free from mesenchyme were micro-dissected from E-13 rat kidney rudiments and placed in an ECM gel suspension composed of type I collagen and growth factor-reduced Matrigel, and cultured in BSN cell-conditioned medium (BSN-CM) supplemented with 10% FCS and growth factors. Details are given elsewhere in the text. The cultured UB was monitored daily by microscopy.

Figure 3: The UB undergoes branching morphogenesis *in vitro* and develops three-dimensional tubular structures in the absence of mesenchyme (Proc. Natl. Acad. Sci., 96, 7330-7335, 1999 incorporated herein by reference—please refer to this paper for color reproductions). E-13 rat UB was isolated and cultured as described herein below. After culture, UBs were fixed at different time points and

processed for DB lectin staining. 3-D reconstructions of confocal images are shown:

a) A freshly isolated UB from an E-13 rat embryonic kidney with a single branched tubular structure; b) The very same UB shown in a) after being cultured for 3 days.

The tissue has proliferated and small protrusions have formed; c) Again, the same

5 UB as shown in a) cultured for 6 days. More protrusions have formed, and the protrusions have started to elongate and branch dichotomously; d) the same UB as shown in a) cultured for 12 days. The protrusions have undergone further elongation and repeated dichotomous branching to form a structure resembling the developing collecting system of a kidney. The white arrows indicate branch points. At higher
10 power, the structures formed in this *in vitro* culture system exhibited lumens. Phase microscopic examination and staining for markers revealed no evidence for contamination by other tissue or cells.

Figure 4: BSN-CM and at least one soluble growth factor are required for branching morphogenesis of the isolated UB (Proc. Natl. Acad. Sci., 96, 7330-

15 7335, 1999 incorporated herein by reference—please refer to this paper for color reproductions). A: The UB cultured in the absence of BSN-CM and growth factors; B: The UB cultured with the mixture of growth factors (including EGF, IGF, HGF, FGF-2, and GDNF) but no BSN-CM; C: The UB cultured in the presence of BSN-CM alone; D: The UB cultured in the presence of both BSN-CM and the mixture of
20 growth factors. All cultures were carried out for about one week and then processed for DB lectin staining. Shown is the three-dimensional reconstruction of confocal images. The isolated UB exhibits branching morphogenesis only in the presence of both BSN-CM and the mixture of growth factors.

Figure 5: BSN-CM contains unique soluble factor(s) for branching
25 **morphogenesis of the isolated UB** (Proc. Natl. Acad. Sci., 96, 7330-7335, 1999

incorporated herein by reference—please refer to this paper for color reproductions). The UBs were cultured in the presence of the key growth factor (GDNF; see Fig. 7) but with different cell conditioned media: A: 3T3 fibroblast cell conditioned medium; B: immortalized UB cell conditioned medium; C: mIMCD cell conditioned medium; D: BSN cell conditioned medium. After culture, the UBs were fixed and processed for DB lectin staining. Only BSN-CM could promote extensive branching morphogenesis of the isolated UB.

Figure 6: GDNF plus BSN-CM is required for branching morphogenesis (Proc. Natl. Acad. Sci., 96, 7330-7335, 1999 incorporated herein by reference—please refer to this paper for color reproductions). The UBs were cultured in the presence of BSN-CM, as in Fig. 4 but with each of single growth factors present in the growth factor mixture. Several examples are shown: A: with EGF alone; B: with FGF-2 alone; C: with HGF alone; D: with GDNF alone. Only GDNF combined with BSN-CM could promote branching morphogenesis of the isolated UB.

Figure 7: GDNF is required for both early and late branching morphogenesis *in vitro*. (Proc. Natl. Acad. Sci., 96, 7330-7335, 1999 incorporated herein by reference—please refer to this paper for color reproductions) A-C: The antibodies against GDNF are neutralizing antibodies. A: UB was cultured in the presence of BSN-CM and GDNF without antibodies; B: same as A, but normal goat IgG antibody were added; C: same as A, but antibodies against GDNF were added. D-F: GDNF is required for branching morphogenesis. The UBs were initially cultured in the presence of BSN-CM and GDNF and then the cultures were washed to remove GDNF at different time points; the UBs were then continuously cultured in BSN-CM without GDNF. To ensure neutralization of residual GDNF in the culture, antibodies against GDNF were added after removal and washing of GDNF from the culture

medium. D: The UB was cultured as in A, but GDNF was removed and antibodies against GDNF were added on the first day of culture; E: Same as D, but the GDNF was removed and antibodies against GDNF were added on the second day of culture; F: Same as D, but the GDNF was removed and antibodies against GDNF were added on the third day of culture (compare with structures in Fig. .3). All cultures were carried out until the fifth day and processed with DB lectin staining. Whenever GDNF is depleted, UB growth and branching morphogenesis is aborted, indicating that GDNF is required for both early and late branching morphogenesis *in vitro*.

Figure 8: The cultured three-dimensional tubular structure exhibits markers of UB epithelium and is functionally capable of inducing nephrogenesis when recombined with metanephric mesenchyme *in vitro*. (Proc. Natl. Acad. Sci., 96, 7330-7335, 1999 incorporated herein by reference—please refer to this paper for color reproductions). The UBs were cultured in the presence of BSN-CM and GDNF and then stained for various markers (A-F). A: Light microscopic phase photograph of cultured UB; B: Staining with DB lectin, a ureteric bud specific lectin which binds to the UB and its derivatives; C: Staining for vimentin, a mesenchymal marker; D: Staining for N-CAM, the early marker for mesenchymal to epithelial conversion in the kidney; E: Staining with PNA lectin, a mesenchymally derived renal epithelial cell marker; F: Staining for cytokeratin, an epithelial marker. G-I: The cultured three-dimensional tubular structure is capable of inducing nephrogenesis when recombined with metanephric mesenchyme. The isolated UB was first cultured 7-10 days as shown in G. Then, the cultured UB was removed from the ECM gel and recombined with freshly isolated metanephric mesenchyme from E-13 rat kidneys. The recombinant was cultured on a Transwell filter for another 5 days. After culture, the sample was double stained with DB lectin (FITC) and PNA lectin (TRITC) as

shown in H and in the enlarged section of H shown in I. Results indicate that the in vitro cultured UB derived structures are capable of inducing nephrogenesis in vitro.

Figure 9: Culture of metanephric mesenchyme. Day 13 embryonic rat kidneys rudiments were microdissected to separate the ureteric bud from the metanephric mesenchyme. The metanephric mesenchyme was then placed in a Transwell tissue culture insert on top of the polycarbonate filter (3 μ m pore size). Media (DME/F12) supplemented with 10% fetal calf serum (FCS) was placed in the bottom of the chamber and the entire setup was incubated at 37°C with 5% CO₂ with 100% humidity. (A) Freshly isolated metanephric mesenchyme. (B) The same metanephric mesenchyme following 5 days in culture.

Figure 10: Subculture of the ureteric bud. Ureteric buds were isolated from E13 rat kidneys and grown in culture for 7 days. At the end of this culture period the ureteric bud was dissected free of the surrounding extracellular matrix and the bud was cut into pieces and subcultured under the same conditions. (A) Originally isolated ureteric bud after seven days of culture. Black box indicates piece of bud that was dissected free and subcultured. (B) Subcultured bud after 24 hrs in culture. (C) Subcultured bud after 4 days in culture. (D) Subcultured bud after 7 days in culture.

Figure 11: Recombination of subcultured bud with freshly isolated metanephric mesenchyme. Ureteric buds were isolated, cultured and subcultured as previously described in Fig. 10. Metanephric mesenchymes were microdissected from E13 day rat embryonic kidneys and placed in close contact with subcultured ureteric bud as in Fig. 8. The recombined tissues were grown in culture for 7 days. Tubular structures are evident at this time.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

1. Introduction

In vitro cell and organ culture models for the study of collecting system development.

Several in vitro cell culture models of tubulogenesis and branching morphogenesis can be used to perform cellular and molecular analyses of these processes that can not be easily accomplished with other models for urinary tract development.

Many techniques have been used to gain insight into the cellular and molecular basis of nephrogenesis. These include genetic approaches (knockouts and transgenics), organ culture and cell culture models. Now, it is clear that each of these approaches has limitations, and it is likely that only through their combined use that the field will arrive at an accurate picture of kidney and urinary tract development. With respect to collecting system development, it is difficult to analyze the molecular processes involved in tubulogenesis and branching morphogenesis in whole animals or whole embryonic kidney organ culture, given the spatiotemporal complexity of kidney development and multiple potential interactions between numerous mesenchymally and epithelial-derived cells in varying stages of differentiation. Until a few years ago, there were no simple *in vitro* systems to study tubulogenesis and branching of renal or renal-derived epithelial cells. In recent years, it has become possible to analyze these processes using renal epithelial cells cultured in extracellular matrix gels under stimulation by soluble growth factors and/or conditioned medium from cells derived from the early metanephric mesenchyme.

Hepatocyte growth factor (HGF), the receptor for which is *c-met*, a RTK, has been known for some time to be able to induce the formation of branching tubular structures when MDCK cells (a renal epithelial cell line) are seeded in Type I collagen matrix gels. Without HGF, these cells develop into cystic structures, but in the presence of HGF, the cells form cytoplasmic processes which eventually develop multicellular branching chords and then into tubular structures. The inventors have previously demonstrated that the HGF-induced structures have apical-basolateral polarity, as determined by immunofluorescence with antisera against marker proteins for apical and basolateral surfaces of polarized tubular epithelial cells (Dev. Biol., 159,535-548, 1993). Thus, HGF is sufficient, in the setting of the appropriate three dimensional extracellular matrix, to produce polarized tubular structures similar to those existing in the differentiated collecting ducts (Dev. Biol., 160, 293-302, 1993; Dev. Biol. 163, 525-529, 1993, Proc. Natl. Acad. Sci., 92, 4412-4416). The inventors have also developed novel cell culture models for branching tubulogenesis using both mature collecting duct cells (22) and embryonic ureteric bud cells (16). The morphogenesis of embryonic UB cells is largely dependent upon growth factors other than HGF (16).

Nevertheless, as inventors show below, inventors have, for the first time, been able to demonstrate that the isolated ureteric bud can undergo impressive branching morphogenesis in the presence of soluble factors, though there is a subsequent requirement for contact with mesenchyme for both elongation and guidance of branching ureteric-bud derived structures, as well as nephron formation. Thus, the inventors have set up unique embryonic cell and organ culture based systems that can help dissect the cellular and molecular basis of kidney growth, morphogenesis and development. Many of these systems were first established by the inventors and have

been exclusively characterized by them. Several of these systems are described below.

Example 1.

Isolation of ureteric bud (UB) epithelium and UB culture (Proc. Natl. Acad. Sci., 86, 7330-7335, 1999 incorporated herein by reference): Kidney rudiments were
5 dissected from timed pregnant Sprague Dawley rats at gestation day 13. (The plug day was designated as day 0). The UB was isolated from mesenchyme by incubating kidney rudiments in 0.1% trypsin in the presence of 50 U/ml DNAase at 37°C for 15 minutes, and by mechanical separation with two fine-tipped minutia pins. For
10 culture, Transwell tissue culture plates and a polycarbonate membrane insert with 3 um pore size were used. The extracellular matrix (ECM) gel (a mixture of type I collagen and Matrigel) was applied on top of the Transwell insert. Isolated UB was suspended in the ECM gel and cultured at the interface of air and medium. All cultures were carried out at 37°C with 5% CO₂ and 100% humidity in DMEM/F12
15 supplemented with 10% Fetal Calf Serum (FCS). Growth factors were added as indicated elsewhere. Culture media were changed weekly if necessary.

Example 2.

Cells and conditioned media: The BSN cell line was derived from day 11.5 mouse embryonic kidney metanephric mesenchyme originally obtained from a mouse line
20 transgenic for the early region of SV-40/large T antigen. As described elsewhere, the BSN cells express the mesenchymal protein marker vimentin, but not classic epithelial marker proteins such as cytokeratin, ZO-1 and E-cadherin (16). Differences in the expression patterns of 588 genes in BSN cells have been analyzed by the inventors on commercially available cDNA grids (Am. J. Physiol.-Renal

Physiol., 277, F:650-F663, 1999), and confirmed the largely non-epithelial character of BSN-cells, though it remains to be determined whether they are mesenchymal or stromal, or have characteristics of both cell types. The SV-40/large T antigen transformed UB cell line and murine inner-medulla collecting duct (mIMCD) cells have been extensively characterized before (16,17,18,19). To obtain conditioned media, a confluent cell monolayer was washed with serum-free medium, and then cultured in serum free medium for another 2-4 days. Various conditioned media were harvested after low speed centrifugation to remove cell debris and then concentrated 10-fold with a Centricon filter with 8 kDa nominal molecular weight cutoff (Millipore, Bedford, MA). In addition, BSN-CM was subfractionated on a heparin-sepharose affinity column (Hitrap Heparin; Pharmacia, NJ). Concentrated BSN-CM (~10X) was applied to a heparin column. After washing the column with Hanks' balanced buffer solution, the heparin bound fraction was eluted with 2 M NaCl in Hanks' balanced buffer solution. After desalting with a PD-10 column (Pharmacia, NJ), the heparin bound fraction's final volume was adjusted to the starting volume. The heparin flow through fraction was collected and its volume was adjusted to the starting volume using a Centricon filter (8 kDa cutoff). The partially purified fractions were assayed for their effect on UB morphogenesis in the presence of GDNF.

20 **Example 3.**

The ECM gel mix: The ECM gel mix was composed of 50% type I collagen (Collaborative Biomedical Product) and 50% growth factor-reduced Matrigel (Collaborative Biomedical Product). The procedure for gelation has been previously described in detail (16) and is incorporated herein.

Example 4.

Induction of nephrogenesis by cultured UB: Isolated UBs were first cultured for 7-10 days as already described. Then, the cultured UB was isolated from the ECM gel by incubation with collagenase (1 mg/ml) and dispase (2 ml/ml) at 37°C for 30 minutes, followed by mechanical separation with fine tipped minutia pins. The UB was then recombined with freshly isolated E-13 rat metanephric mesenchyme and co-cultured on a transfilter for another 5 days in DMEM/F12, plus 10% FCS.

Example 5.

Lectin staining: 1) Dolichos Biflorus (DB) lectin: Tissues were fixed with 2% paraformaldehyde for 30 minutes at 4°C, permeabilized with 0.1% Saponin and then incubated with fluorescent conjugated DB (50 ug/ml, Vector) in a moisturized chamber for 60 minutes at 37°C. After extensive washing, tissues were post-fixed in 2% paraformaldehyde again for 5 minutes and viewed using a laser scanning confocal microscope. The specificity of DB lectin binding has been demonstrated previously (20). 2) Peanut agglutinin (PNA) lectin: Tissues were fixed with 2% paraformaldehyde for 30 minutes at 4°C; blocked with 50 mM NH₄Cl overnight at 4°C, followed by an incubation with 1% gelatin in 0.075% Saponin for 30 minutes at 37°C (21). After two washes with Neuraminidase buffer (150 mM NaCl, 50mM Na-Acetate, pH 5.5), tissues were incubated with Neuraminidase (1 U/ml) for 4 hours at 37°C and then with Rhodamine-conjugated PNA (50 ug/ml) for 60 minutes at 37°C. Tissues were post-fixed with 2% paraformaldehyde and viewed with a laser scanning confocal microscope.

Example 6.

Immunocytochemistry: Tissues were fixed with either 2% paraformaldehyde at 4⁰C or 100% methanol at -20⁰C. Tissues were permeablized with 0.1% Saponin and non-specific binding was blocked with fetal 100% FCS***. The incubations with
5 primary and secondary antibodies were carried out for 60 minutes at 37⁰C. The staining with FITC or TRITC-conjugated antibodies was viewed with a laser scanning confocal microscope.

Example 7.

Confocal Analysis: Confocal images were collected with a laser scanning
10 confocal microscope (Bio-Rad MRC 1024, Bio-Rad, CA). Each three-dimensional picture was reconstructed from a set of 10 um serial sections, which spanned the tissue. Images were processed with Laser SharpTM (Bio-Rad) and PhotoshopTM (Adobe, CA) software.

DISCUSSION

15 The abovementioned examples define a new method of producing an active, functional embryonic kidney or fragment.

Immortalized UB cells have been shown by the inventors to undergo impressive morphogenesis in the presence of soluble factors (16) when seeded in extracellular matrix gels containing Type I collagen mixed with growth factor-
20 depleted Matrigel, a basement membrane extract derived from EHS sarcoma cells (Proc. Natl. Acad. Sci., 86, 7330-7335, 1999 incorporated herein by reference). . A conditioned medium elaborated by BSN cells (BSN-CM), an immortalized line

derived from the early metanephric mesenchyme that has been developed by the inventors, has been shown to induce the formation of branching tubular structures, some of which have apparent lumens (16); the key activity in BSN-CM was shown to be distinct from a number of growth factors known to induce morphogenesis in

5 mature kidney epithelial cell lines. The results from these cell culture studies suggest that the program for branching morphogenesis exists within UB cells and does not require direct contact with metanephric mesenchymal cells. Reasoning that the conditions for branching morphogenesis of isolated UB tissue might be similar to this in vitro cell culture system employing a UB cell line, the inventors separated

10 embryonic rat kidney UB from the metanephric mesenchyme prior to induction and cultured the isolated UB (free from mesenchyme) in a mixture of collagen and growth factor depleted Matrigel (Fig. 2). After trying many different conditions, dichotomous branching morphogenesis resembling the structures of the developing embryonic kidney was achieved when the isolated UB was cultured in the presence

15 of a combination of BSN-CM and a mixture of growth factors (EGF, HGF, IGF, FGF-2 and GDNF)(Fig. 3). The growth factor mixture was chosen based upon the effects of individual factors on *in vitro* morphogenesis of cultured UB and mIMCD cells previously performed by the inventors (16, 22, 23, 24); HGF and EGF induce complex morphogenetic changes in UB and mIMCD cells, while IGF and FGF-2

20 induce some morphogenetic changes in UB cells. Because of strong genetic and cell culture data supporting the role of GDNF/cRET in early UB morphogenesis and survival of UB-derived cells (11,12,25), GDNF was also added to the mixture.

At gestational day 13, rat UB is a “T” shaped epithelial tubule (Fig. 3a). *In vivo*, this single branched epithelial tubule undergoes repeated dichotomous

25 branching and forms the “tree” shaped collecting system through interactions with

metanephric mesenchyme (26). This epithelial-mesenchymal interaction is thought to be required for the tubular/ductal development of several organ systems, such as lung, pancreas and mammary gland (27,28,29). In the inventors system, isolated UB (free from metanephric mesenchyme) can be cultured and induced to undergo branching morphogenesis *in vitro*. The cultured UB branched dichotomously with formation of structures that had apparent lumens. Each branch had both tubular and ampullary portions (Fig. 3b through d). Staining with lectins and antibodies indicated that the tubular structures remained UB-derived and epithelial in character. Both cell proliferation and branching morphogenesis appeared to occur simultaneously. In most cases, after 48 hours of culture, UB epithelial tissues started to increase in size and developed small protrusions from the “T” shaped ureteric bud. After 3-4 days of culture, those protrusions started to elongate, and the tips of the elongated structure started to branch dichotomously. The structures formed from the cultured UB revealed no staining with vimentin antibodies and peanut lectin (PNA), markers for mesenchymally derived elements, further supporting the notion that, in the appropriate milieu of soluble factors, complex branching of the UB can occur in the absence of direct contact with the metanephric mesenchyme. Moreover, growth of isolated UB was observed for up to 3-4 weeks, with many generations of branching.

BSN-CM played a critical role in this morphogenetic process (Fig. 4A-D). In the absence of BSN-CM, growth factors had no effect on proliferation and branching morphogenesis of the UB (Fig. 4B). Only when BSN-CM was present, did the UB develop into a three-dimensional tubular structure (Fig. 4D and 5D). To examine whether BSN-CM contained unique factors for the branching morphogenesis of the UB, conditioned media from different cell lines were compared. Neither conditioned

medium derived from Swiss 3T3 fibroblasts (an inducer of MDCK cell branching tubulogenesis in Type I collagen) nor from UB cells or mIMCD3 cells was capable of substituting for BSN-CM (Fig. 5A-C), suggesting that the BSN cells retain the ability to secrete a relatively unique factor, or set of factors, made by the metanephric mesenchyme and required for UB branching morphogenesis (Fig. 5D). This activity was heat-sensitive. When BSN-CM was fractionated over a heparin sepharose column, only the heparin bound fraction exhibited morphogenetic activity.

Nevertheless, the factor (or a set of factors) in BSN-CM was not sufficient to induce UB branching morphogenesis. In the absence of the growth factor mixture, the UB underwent apoptosis as determined by the TUNEL assay (data not shown). To further define conditions for *in vitro* UB branching morphogenesis, Inventors examined whether any single growth factor present in the growth factor mixture could, in combination with BSN-CM, induce UB branching morphogenesis. The combination of BSN-CM and GDNF, but no other combination, was found to be sufficient to induce the formation of three-dimensional branching structures comparable to those observed with BSN-CM and the growth factor mixture (Fig. 6A-D). Consistent with this observation, the combination of BSN-CM and GDNF prevented the UB from undergoing apoptosis and facilitated UB proliferation (data not shown). Since GDNF alone could not induce branching morphogenesis in the absence of BSN-CM, a factor or factors present in the BSN-CM must be required for the action of GDNF in the induction of UB branching morphogenesis. While studies from others have indicated that GDNF is involved in the initial formation of the UB (30,31), it has not been established whether GDNF is required for the further branching morphogenesis of the UB. Therefore, the UB was first cultured in the presence of BSN-CM and GDNF, and then in the absence of GDNF after repeatedly

washing away GDNF from the culture and then adding antibodies known to neutralize GDNF in this system (Fig. 7A-C). Withdrawal of GDNF from the culture system blocked further UB branching morphogenesis, suggesting that GDNF is not only involved in early UB formation but also in further iterations of UB branching (Fig. 7D-F and compare Figs. 7E and 7F with Figs. 3b and 3c). In this regard, it is interesting to note that mesenchymal cell contact or some other soluble factor may be able to partially compensate for GDNF, at least under certain conditions in whole organ culture, since *c-RET* antisense oligonucleotides are not strongly inhibitory of continued branching of the UB when added after induction (32).

To characterize the complex tubular structures of the *in vitro* cultured UB, expression of several markers was examined. The cultured UB structures exhibited positive staining with DB lectin and cytokeratin antibodies, but negative staining with PNA lectin and vimentin antibodies. The expression pattern of these markers confirmed that the tubular structures formed *in vitro* were UB-derived (Fig 8A-F). Nevertheless, a key issue was whether the cultured UB retained the capacity for induction of nephric units in the metanephric mesenchyme. When this was tested, it was confirmed that the tubular structures resulting from the cultured UB were capable of eliciting mesenchymally-derived metanephric nephronal structures and of being incorporated into the nephric unit when recombined with the freshly isolated metanephric mesenchyme (Fig. 8G-I). As shown by PNA staining, most nephrons were located at the periphery of the cultured tissue, where tips of new UB branches were forming. All formed mesenchymally-derived nephronal structures appeared connected with the tubular structures of UB. In addition, the cultured UB structures continued to respond to the inductive effect of mesenchyme by elongating further into the mesenchymal tissue (Fig. 8H-I). Together, these results indicate that the

structures grown *in vitro* are UB-derived epithelial tubules and retain induction competence even after many days of *ex vivo* culture. The results also suggest that while the factor(s) in BSN-CM plus GDNF may be sufficient for the initial branching processes, later events in UB morphogenesis (e.g. elongation and establishing the pattern of branching) may require contact with mesenchyme.

Thus, by utilizing Inventors' novel model system, Inventors have found that, in contrast to the widely held view that the complex arborization of the UB during kidney development is dependent upon direct contact between cells of the metanephric mesenchyme and cells of the UB, a substantial degree of branching morphogenesis can be mediated by soluble factors alone. Therefore, the branching program exists within the UB itself after it is formed from the Wolffian Duct, and soluble factors can trigger its initiation and continuation. No singular soluble factor, however, appears sufficient. A combination of GDNF and an activity, or set of activities, present in BSN-CM is necessary. Whether this latter activity is the same as that which induces the formation of branching tubules with lumens of UB cells in culture remains to be determined (16). It seems very likely that more direct mesenchymal interactions with the UB are important for establishing the direction of branching events since the cultured UB-derived structures lack directionality, and only when the cultured UB was recombined with metanephric mesenchyme did directionality and elongation occur (Fig. 8H-I). Epithelial-mesenchymal cell-cell contact is probably essential for the later steps in the development of UB/collecting system. Additional mechanisms are likely to be involved in the formation of junctions between mesenchymally-derived nephronal segments and collecting tubules and the development of tertiary structures of the collecting tubule, such as the formation of arcades. Moreover, contact with the mesenchyme might provide a

“stop” mechanism for kidney growth since Inventors found that the isolated UB continued to grow *in vitro* as long as soluble factors were provided.

Inventors’ data also clarify the role of GDNF in kidney development. To date, GDNF has been implicated in initial UB outgrowth and early survival, but its role in
5 branching morphogenesis of the UB has been debated. Inventors’ data indicate that GDNF, in combination with factors in BSN-CM, supports true morphogenesis of the UB, at least *in vitro*. GDNF is required for not only the initial outgrowth but also the subsequent branching morphogenesis of the UB.

Finally, these results suggest that it be worth reevaluating the role of cell
10 contact versus soluble factors in a wide variety of epithelial tissues where intimate cellular interactions between epithelial and mesenchymal tissues are thought to play a crucial inductive role, particularly with respect to branching morphogenesis. In the developing kidney, and perhaps in many of these other tissues, the role of cell contact may be facilitatory rather than crucial for early branching morphogenesis per se,
15 although it may be essential for the establishment of vectoriality and later events in differentiation (Proc. Natl. Acad. Sci., 86, 7330-7335, 1999 incorporated herein by reference).

While the present invention has now been described in terms of certain preferred embodiments, and exemplified with respect thereto, one skilled in
20 the art will readily appreciate that various modifications, changes, omissions and substitutions may be made without departing from the spirit thereof. It is intended, therefore, that the present invention be limited solely by the scope of the following claims.

CLAIMS

What is claimed is:

1. A method for *in vitro* constructing of a functional mammalian organ or a
5 fragment thereof, comprising:
culturing and propagating embryonic explants, tissues or cells by
isolating the tissues or cells and growing them in culture,
permitting the culture to form multiple branches,
dissecting out the individual branch tips,
10 reculturing in the presence of serum, growth factor mix, conditioned medium
and nutrient-rich medium for several generations;
simultaneously culturing and propagating isolated embryonic or fetal metanephric
mesenchyme by
dissecting out fetal mesenchyme at the time of induction,
15 culturing mesenchymal tissue in the presence of serum, growth factor mix,
conditioned medium and nutrient-rich medium,
partitioning the mesenchyme into multiple pieces and growing each piece
separately, and
inducing vasculogenesis by subjecting grown mesenchyme to substrate deprivation
20 or addition of soluble factors;
recombining each vascularized mesenchyme with each cultured bud in a matrix in
which *in vitro* angiogenesis has begun; and
growing in richest medium conditions to ensure continued vasculogenesis.

2. A method for *in vitro* culturing and propagating ureteric bud tissue, comprising:
- isolating embryonic kidney rudiments by dissection,
- isolating ureteric bud tissue fragments from mesenchyme by
- 5 incubating said kidney rudiments with a proteolytic enzyme in the presence of DNAase and/or by mechanical separation;
- suspending said isolated ureteric bud fragments in a gel matrix;
- placing the gel/fragment composition on porous polycarbonate membrane inserts in wells of tissue culture plates;
- 10 adding growth factors to the culture wells;
- maintaining the gel composition at the interface of air and medium until said fragments form multiple tubular branches inside the gel matrix;
- dissecting out distal individual branch tips formed during culture; and
- reculturing said branch tips in the presence of serum, growth factor mix, cell
- 15 conditioned medium and nutrient-rich medium for several generations.
3. The method according to claim 2, wherein the mechanical separation is accomplished by manual dissection.
4. The method according to claim 2, wherein the mechanical separation is accomplished by laser separation and capture.
- 20 5. The method according to claim 2, wherein the growth factor mix comprises a glial cell line-derived neurotrophic factor or functional equivalent thereof.
6. The method according to claim 2, wherein the added conditioned medium comprises a growth promoting constituent or inducer of differentiation or morphogenesis.

7. The method according to claim 2, wherein the extracellular matrix gel comprises a mixture of type I collagen and Matrigel, or an equivalent matrix.
8. A method for *in vitro* culturing and propagation of metanephric mesenchyme, comprising:
- 5 dissecting out fetal kidney mesenchyme tissue [at the time of induction];
culturing said mesenchymal tissue in the presence of serum, growth factor mix,
mesenchymal and/or bud cell conditioned medium and nutrient-rich medium;
partitioning the cultured mesenchyme into multiple pieces and growing each piece
separately in culture; and
- 10 subjecting grown mesenchyme to substrate deprivation or addition of vasculogenic
growth factors in order to induce vasculogenesis.
9. A method for *in vitro* engineering and constructing a mammalian kidney,
comprising:
- culturing and propagating a ureteric bud by
- 15 isolating the ureteric bud in culture,
permitting the culture to form multiple branches,
dissecting out the individual branch tips,
reculturing in the presence of serum, growth factor mix,
mesenchymal and/or bud cell conditioned medium and nutrient-rich medium
- 20 for several generations;
culturing and propagating isolated embryonic or fetal metanephric mesenchyme by
dissecting out fetal mesenchyme at the time of induction,
culturing mesenchymal tissue in the presence of serum, growth factor mix,
mesenchymal and/or bud cell conditioned medium and nutrient-rich medium,
- 25 partitioning the mesenchyme and growing each piece separately, and

- inducing vasculogenesis by subjecting grown mesenchyme to substrate deprivation or addition of vasculogenic growth factors;
recombining each vascularized mesenchyme piece with each cultured bud in a matrix in which *in vitro* angiogenesis has begun; and
5 growing in richest medium conditions to ensure continued vasculogenesis.
10. The method according to claim 9, wherein the recombined tissues are implanted into a recipient without prior induction of vasculogenesis.
11. A functional mammalian kidney constructed *in vitro* from isolated embryonic or fetal kidney tissue or cells that were cultured in rich medium having present a
10 mixture of growth factors and inducer substances, comprising:
an isolated ureteric bud propagated in culture to produce a functioning nephron;
metanephric mesenchyme propagated from cultured embryonic mesenchymal tissue fragments or cells; and
recombination of propagated ureteric bud and metanephric mesenchyme
15 wherein said recombination in culture results in a functioning kidney or a functionally equivalent fragment thereof.

ABSTRACT

A method for constructing a stable bioactive mammalian embryonic kidney is described herein. A kidney so constructed requires no artificial support, nor porous man made membranes or tubing to effectuate its biological function of filtering body fluids. A single donor embryonic kidney, or fragment thereof, can produce a great number of functional kidneys suitable for treating subjects with various kidney disorders. It is anticipated that said *in vitro* produced kidney would be less, or not at all, antigenic when transplanted into a subject, because of its embryonic character and artificial propagation in culture. This method of producing a functional organ can be useful in cloning other organ structures containing inducible epithelial tissues.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10





Figure 11

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) _____ of Declaration were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Scanned copy is best available.